-

On-Site at ASCO GU 2026 | Prof. Thomas Powles: HER2-Targeted Therapy Is Transforming Urothelial Carcinoma Care, with Chinese Innovation Reshaping the Global Landscape
The 2026 ASCO Genitourinary Cancers Symposium (ASCO GU) has once again opened as one of the most authoritative and influential global meetings in genitourinary oncology. As always, it sets the direction for advances in urothelial carcinoma, prostate cancer, and renal cell carcinoma. This year, precision-targeted therapy in urothelial carcinoma stands firmly at the center of…
-

Breaking the Adjuvant Monotherapy Standard: LITESPARK-022 Study Shows 28% Reduction in Recurrence Risk for High-Risk ccRCC
At the American Society of Clinical Oncology (ASCO) Annual Meeting, Dr. Toni K. Choueiri from the Dana-Farber Cancer Institute and Harvard Medical School presented the primary results of the LITESPARK-022 study (NCT05239728). As the largest randomized, double-blind, Phase 3 trial to date in the adjuvant immunotherapy setting, LITESPARK-022 evaluated the efficacy of pembrolizumab plus belzutifan…
-

Redefining First-Line nccRCC Treatment: Fruquintinib plus Serplulimab Combination Achieves 97.2% Disease Control Rate
At the 2025 Annual Meeting of the American Society of Clinical Oncology (ASCO), Professor Jiwei Huang, on behalf of the research team, delivered an oral presentation reporting the latest efficacy and safety data from a multicenter, single-arm, Phase II clinical study. The trial evaluated fruquintinib in combination with serplulimab as a first-line treatment for patients…
-

Transcending HER2 Expression Boundaries: RC48 Achieves Breakthrough Benefits in Both HER2-Positive and HER2-Low Advanced Urothelial Carcinoma
At a recent international oncology conference, Professor Tom Powles from the Barts Cancer Centre in London presented the latest results from the RC48-G001 study. This global, multicenter Phase 2 trial evaluated disitamab vedotin (RC48) in patients with HER2-expressing, previously treated advanced urothelial carcinoma (UC). As a HER2-targeted antibody-drug conjugate (ADC) utilizing a monomethyl auristatin E…
-

Overcoming “Low-Shedding” Barriers: Prof. Taigo Kato Highlights the Value of WGS-Based ctDNA Monitoring in Postoperative RCC
At a recent academic session, Professor Taigo Kato from the Osaka University Graduate School of Medicine presented the preliminary results of the MONSTAR-SCREEN-3 study. The study investigates the clinical utility of an ultra-sensitive whole-genome sequencing (WGS)-based circulating tumor DNA (ctDNA) assay for the detection of molecular residual disease (MRD) in patients with resectable renal cell…
-

KEYNOTE-905 Update: EV plus Pembrolizumab Achieves 57% pCR and Significantly Extends DFS in Muscle-Invasive Bladder Cancer
At a recent international medical congress, Dr. Steffen Rausch from the University Hospital Tübingen presented the latest analysis of pathological outcomes and disease-free survival (DFS) from the KEYNOTE-905 study. This randomized, open-label Phase III trial evaluates the efficacy and safety of perioperative enfortumab vedotin (EV) combined with pembrolizumab in patients with muscle-invasive bladder cancer (MIBC)…
-

Balancing Survival Benefit and Quality of Life: Clinical Trade-offs in Adjuvant Immunotherapy Based on RAMPART PRO Data
At a recent international academic symposium, Dr. Sophie Merrick from the Medical Research Council Clinical Trials Unit at University College London (UCL) reported the Patient-Reported Outcome (PRO) data from the RAMPART trial. The study aimed to evaluate the dynamic impact of adjuvant durvalumab plus tremelimumab versus active monitoring on the quality of life (QoL) of…
-

Significant Improvement in PFS and DOR: LITESPARK-011 Validates Clinical Benefit of a Novel Combination Following Immunotherapy Progression
For patients with advanced renal cell carcinoma (RCC) who have progressed after anti-PD-(L)1 therapy, a consensus standard of care is currently lacking. Belzutifan, a first-in-class HIF-2α inhibitor, combined with the VEGFR-TKI lenvatinib, has emerged as a promising therapeutic strategy. At a recent academic conference, Professor Robert J. Motzer from Memorial Sloan Kettering Cancer Center (MSKCC)…